Eric Simpson, MD, MCR

Eric Simpson, MD, MCR, of the Department of Dermatology at Oregon Health & Science University in Portland.

Articles by Eric Simpson, MD, MCR

Tilrekimig Meets EASI-75 Goal in Atopic Dermatitis, With Eric Simpson, MD

October 8th 2026

Simpson discusses 16-week phase 2 data on the IL-4/IL-13/TSLP trispecific, including vIGA gaps and conjunctivitis findings.

Future Directions for Atopic Dermatitis Management

ByLinda Stein Gold, MD,Raj Chovatiya, MD, PhD,Eric Simpson, MD, MCR,Alexandra K. Golant, MD

June 1st 2022

Raj J. Chovatiya, MD, PhD; Alexandra K. Golant, MD; Eric Simpson, MD, MCR; and Linda Stein Gold, MD, share clinical pearls and discuss the future treatment landscape for atopic dermatitis.

Patient Challenges With Available Therapies for Atopic Dermatitis

ByLinda Stein Gold, MD,Raj Chovatiya, MD, PhD,Eric Simpson, MD, MCR,Alexandra K. Golant, MD

June 1st 2022

Alexandra K. Golant, MD; Raj J. Chovatiya, MD, PhD; and Eric Simpson, MD, MCR, discuss challenges adolescent and adult patients face with current oral and topical therapies and optimizing disease management.

JAK Inhibitors in Clinical Practice for Atopic Dermatitis Treatment

ByLinda Stein Gold, MD,Raj Chovatiya, MD, PhD,Eric Simpson, MD, MCR,Alexandra K. Golant, MD

June 1st 2022

Experts in the management of atopic dermatitis assess the use of JAK inhibitors in clinical practice and considerations for treatment selection for patients with atopic dermatitis.

Using Topical Versus Oral JAK Inhibitors in Atopic Dermatitis

ByLinda Stein Gold, MD,Raj Chovatiya, MD, PhD,Eric Simpson, MD, MCR,Alexandra K. Golant, MD

May 25th 2022

Alexandra K. Golant, MD; Raj J. Chovatiya, MD, PhD; and Eric Simpson, MD, MCR, share their approach to prescribing decisions for oral and topical JAK inhibitors for patients with atopic dermatitis.

Addressing JAK Inhibitor Boxed Warnings in Atopic Dermatitis

ByLinda Stein Gold, MD,Raj Chovatiya, MD, PhD,Eric Simpson, MD, MCR,Alexandra K. Golant, MD

May 25th 2022

Drs Alexandra K. Golant, Raj J. Chovatiya, Linda Stein Gold, and Eric Simpson comment on clinical implications of boxed warnings for the utilization of JAK inhibitors when treating atopic dermatitis.

JAK Inhibitor Therapies for Atopic Dermatitis

ByLinda Stein Gold, MD,Raj Chovatiya, MD, PhD,Eric Simpson, MD, MCR,Alexandra K. Golant, MD

May 18th 2022

Eric Simpson, MD, MCR, leads a discussion on current FDA approved topical and systemic JAK inhibitors for the management of atopic dermatitis.

Patient Selection of JAK Inhibitors in Atopic Dermatitis

ByLinda Stein Gold, MD,Raj Chovatiya, MD, PhD,Eric Simpson, MD, MCR,Alexandra K. Golant, MD

May 18th 2022

Alexandra K. Golant, MD, highlights factors to consider when recommending the use of JAK inhibitors to manage atopic dermatitis for various patient populations.

Role of JAK Inhibitors for Atopic Dermatitis Treatment

ByLinda Stein Gold, MD,Raj Chovatiya, MD, PhD,Eric Simpson, MD, MCR,Alexandra K. Golant, MD

May 11th 2022

Raj J. Chovatiya, MD, PhD, provides an overview of JAK inhibitors and their use in atopic dermatitis treatment.

Treatment Goals and Challenges for Atopic Dermatitis Management

ByLinda Stein Gold, MD,Raj Chovatiya, MD, PhD,Eric Simpson, MD, MCR,Alexandra K. Golant, MD

May 11th 2022

Alexandra K. Golant, MD; Raj. Chovatiya, MD, PhD; and Eric Simpson, MD, MCR, discuss goals of therapy for patients with atopic dermatitis and challenges physicians face in management of the disease.